ArticleThe oncologist2022

Pembrolizumab and Trastuzumab in High Tumor Mutational Burden and POLE-Mutated HER2-Positive Refractory Breast Cancer.

Li Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.